TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives., PMID:40332725
AI-enhanced profiling of phage-display-identified anti-TIM3 and anti-TIGIT novel antibodies., PMID:40134430
Dual nanobody-redirected and Bi-specific CD13/TIM3 CAR T cells eliminate AML xenografts without toxicity to human HSCs., PMID:39976474
Impact of T Cell Exhaustion and Stroma Senescence on Tumor Cell Biology and Clinical Outcome of Head and Neck Squamous Cell Carcinomas., PMID:39769271
Tim-3 pathway dysregulation and targeting in sepsis-induced immunosuppression., PMID:39696711
Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020-2024)., PMID:39653621
Ubiquitination and degradation of MHC-II by Tim-3 inhibits antiviral immunity., PMID:39546827
Selenopolysaccharide Isolated from Lentinula edodes Mycelium Affects Human T-Cell Function., PMID:39519128
The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells., PMID:39396768
Surface Immune Checkpoints as Potential Biomarkers in Physiological Pregnancy and Recurrent Pregnancy Loss., PMID:39273326
Phenotypic profiling of human induced regulatory T cells at early differentiation: insights into distinct immunosuppressive potential., PMID:39264416
[Research progress on T-cell immunoglobulin mucin 3/galectin 9 (TIM-3/galectin-9) in tumour immunity]., PMID:39215674
The expression of immune checkpoint proteins PD-L1 and TIM3 in mouse and human head and neck squamous cell carcinoma., PMID:39090710
In chronic spontaneous urticaria, increased Galectin-9 expression on basophils and eosinophils is linked to high disease activity, endotype-specific markers, and response to omalizumab treatment., PMID:39021347
Gene expression profile of immune-check point in response to Trastuzumab therapy in patients with HER-2 positive breast cancer., PMID:39008597
TIM-3 Expression in Endometriosis., PMID:38924299
Investigation of the Status of Immune Checkpoint Molecules in Meningiomas by Immunohistochemistry., PMID:38874241
Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia., PMID:37962843
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors., PMID:37567938
Autoimmune thyroid disease disrupts immune homeostasis in the endometrium of unexplained infertility women-a single-cell RNA transcriptome study during the implantation window., PMID:37501789
A spatially resolved timeline of the human maternal-fetal interface., PMID:37468587
IL8 derived from macrophages inhibits CD8+ T-cell function by downregulating TIM3 expression through IL8-CXCR2 axis in patients with advanced colorectal cancer., PMID:37331296
PD-1 AND TIM-3 BLOCKING CANNOT ENHANCE APOPTOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS INDUCED BY PERIPHERAL BLOOD CD8+ T CELLS., PMID:36811540
Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases., PMID:36739094
Contribution of the TIM-3/Gal-9 immune checkpoint to tropical parasitic diseases., PMID:36509129
Cutting edges and therapeutic opportunities on tumor-associated macrophages in lung cancer., PMID:36439090
Tim-3 downregulation by Toxoplasma gondii infection contributes to decidual dendritic cell dysfunction., PMID:36303229
Galectin-9 contributes to the pathogenesis of atopic dermatitis via T cell immunoglobulin mucin-3., PMID:35967337
Noninvasive Prediction of Immune Rejection After Liver Transplantation with T cell immunoglobulin domain, and mucin domain-3., PMID:35918193
Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An in vitro study., PMID:35900543
The prospect of targeting T cell immunoglobulin and mucin-domain containing-3 in renal cell carcinoma immunotherapy., PMID:35700044
Role of Soluble T-Cell Immunoglobulin Mucin Domain-3 in Differentiating Nontuberculous Mycobacterial Lung Disease from Pulmonary Colonization., PMID:35312611
NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division., PMID:34716584
Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3)., PMID:34597046
Differences in Immune Checkpoints Expression (TIM-3 and PD-1) on T Cells in Women with Recurrent Miscarriages-Preliminary Studies., PMID:34575293
Phosphatidylserine binding directly regulates TIM-3 function., PMID:34435619
Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype., PMID:34324022
Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells., PMID:34158344
Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy., PMID:34149690
Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers., PMID:34129290
Increased TIM-3+PD-1+ NK cells are associated with the disease activity and severity of systemic lupus erythematosus., PMID:34101055
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors., PMID:33883177
One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia., PMID:33868234
High levels of Tim-3+Foxp3+Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large B cell lymphoma patients., PMID:33864956
The inhibitory receptor Tim-3 fails to suppress IFN-γ production via the NFAT pathway in NK-cell, unlike that in CD4+ T cells., PMID:33832435
TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer., PMID:33823818
TIM-3 regulates the NETs-mediated dendritic cell activation in myeloperoxidase-ANCA-associated vasculitis., PMID:33734972
Immune checkpoint markers and anti-CD20-mediated NK cell activation., PMID:33615552
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy., PMID:33547304
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody., PMID:33514524
For research use only. Not for human or drug use.
